Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHND9041 vs Afatinib in First-line EGFR-mutated Advanced NSCLC
CTR20212176Phase 3Completed
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FHND-9041 in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. Started Aug 2021; status: completed.
02
Drugs
FHND-9041
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212176.